ClinicalTrials.gg
CompletedNCT05785780Updated Nov 6, 2026

Aim 3, Optimizing CRC Screening in Patients With Diabetes in Safety-net Primary Care Settings

An interventional study of Targeted CRC Screening Toolkit in Colorectal Cancer Screening and Diabetes Mellitus, Type 2, sponsored by Rutgers, The State University of New Jersey. Completed at 1 site in United States. Open to participants aged 50 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Nov 2022, registered Mar 2023).
Updated Nov 6, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
50 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey — 5 open to participants now, 5 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Rutgers, The State University of New Jersey.

Enrollment
11th of 12
13 · median 54
Started
2022
the only one that year
No phase
11 of 12
4 open now
Registered
5th of 12
by date

Among the 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey, this one is the 11th largest by enrollment, is the only one that started in 2022, is one of 11 with no phase, and was the 5th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 50 Years to 74 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey, or all of them as a file.
02

Study summary

This mixed methods study evaluates the effectiveness and feasibility of a multi-level (patient, team, organizations) intervention to optimize CRC screening for patients with diabetes in primary care safety-net settings.

Read the detailed description

Aim 3 is a hybrid type 2 effectiveness-implementation pilot study in six primary care safety net clinics. This single-arm study uses a pre-post design to evaluate the targeted implementation strategies impact on: (1) preliminary effectiveness and (2) implementation (i.e., feasibility and acceptability) and a mixed-method comparative case study learning evaluation for safety-net primary care adoption and implementation. Implementation strategies that will be tested were developed through a stakeholder engaged, community-based participatory implementation planning approach. This study uses a tailored combination of implementation strategies that include but are not limited to: identification of patient and practice-level barriers, patient education matierals, patient reminders provider/clinical team education, clinical champions, and audit and feedback. The impact of this evaluation will be measure using mixed methods to assess Exploration, Preparation, Implementation factors related to how organizational and contextual variables affect adoption and implementation for targeting CRC screening among patients with diabetes in safety net clinics at 12 months post intervention. Aim 3 surveys 20 clinicians and staff from 6 clinics (n=120) and conducts key-informant interviews with 8 clinic and staff members at pre- and post-implementation (who have participated in the survey; n=96) and evaluates aggregate data for 30 patients across six clinics (n=180).

03

Conditions studied

  • Colorectal Cancer Screening
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
50 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of diabetes mellitus;
  • Participants not up-to-date with CRC screening based on electronic health record (e.g. FOBT/FIT in last year; flexible sigmoidoscopy within four years; or colonoscopy within nine years);
  • Age-eligible for CRC screening (50-74 years of age);
  • Participants in process of undergoing screening are eligible for participation if they have a FIT/FOBT incomplete test ordered for more than six months or a sigmoidoscopy or colonoscopy referral not completed for greater than one year.

Exclusion criteria

Exclusion Criteria:

  • Medical conditions not concordant with standard CRC screening intervals (e.g. prior CRC diagnosis, inflammatory bowel disease, renal failure, etc.).
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Targeted CRC Screening Toolkit

    Based on national survey data and a community engagement participatory implemention planning group, a tailored combination of widely accepted implementation strategies will be adapted for targeting CRC screening for patients with diabetes. These strategies include but are not limited to: identification of patient and practice-level barriers, patient education, provider reminders, and audit and feedback.

    Behavioral: Targeted CRC Screening Toolkit

Interventions

  • BehavioralTargeted CRC Screening Toolkit

    Strategies in the toolkit include but are not limited to: identification of patient and practice-level barriers, routine tailored patient reminders, provider reminders, \& clinic staff feedback.

06

What researchers measure

Primary outcomes

  1. Colonoscopy uptake

    Preliminary effectiveness: Clinic-level proportion of participants who complete a colonoscopy

    Time frame: 12 months

  2. Up-to-date CRC screening

    Preliminary Effectiveness: Clinic-level proportion of participants who receive any CRC screening

    Time frame: 12 months

Secondary outcomes

  1. Rate of CRC Screening Uptake by Glucose Control (Controlled vs. Uncontrolled) Among Participants with Type 2 Diabetes

    Preliminary Effectiveness: Clinic-level CRC screening by glucose control (controlled vs. uncontrolled)

    Time frame: 12 months

Other outcomes

  1. Participant Acceptability

    Implementation: participants opt-out and non-adherence rates based on proportion of overall eligible participants

    Time frame: 12 months

  2. Implementation Fidelity

    Clinic-level proportion of eligible participants who were contacted for screening based on implementation plan targets

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Publications

  • O'Malley DM, Crabtree BF, Kaloth S, Ohman-Strickland P, Ferrante J, Hudson SV, Kinney AY. Strategic use of resources to enhance colorectal cancer screening for patients with diabetes (SURE: CRC4D) in federally qualified health centers: a protocol for hybrid type ii effectiveness-implementation trial. BMC Prim Care. 2024 Jul 5;25(1):242. doi: 10.1186/s12875-024-02496-0. PubMed 38969987 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Jul 2026, 44 months.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 44 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Sep 2026 → Jul 2026 and completion Sep 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2023
First posted
Mar 27, 2023
StartActual
Nov 1, 2022
Primary completionActual
Jul 28, 2026was Sep 2026
CompletionActual
Jul 28, 2026was Sep 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Nov 6, 2026
Primary completion
Sep 30, 2026→Jul 28, 2026 (actual)
Nov 6, 2026
Study completion
Sep 30, 2026→Jul 28, 2026 (actual)
Nov 6, 2026
Enrollment
30 (estimated)→13 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Enrolling by invitation→Completed
    Primary completion Sep 30, 2026→Jul 28, 2026 (now actual)
    Study completion Sep 30, 2026→Jul 28, 2026 (now actual)
    Enrollment 30 (estimated)→13 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05785780
Responsible party
Denalee O'Malley (Assistant Professor, Rutgers, The State University of New Jersey) — Principal investigator
First posted
Mar 27, 2023
Start date
Nov 1, 2022
Primary completion
Jul 28, 2026
Completion
Jul 28, 2026
Last update
Nov 6, 2026

Study contacts

Denalee O'Malley, PhD
principal investigator · Rutgers Robert Wood Johnson Medical School; Rutgers Cancer Institute of New Jersey

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion